Effect of Ciprofol on Intraoperative Hypotension in Elderly Patients Receiving Renin-angiotensin System Inhibitors
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Apr 28, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a medication called ciprofol on preventing low blood pressure during surgery in elderly patients who take certain heart medications known as renin-angiotensin system inhibitors. Low blood pressure during surgery can lead to serious problems, especially for older adults, so researchers want to see if ciprofol can help keep blood pressure stable and reduce the risk of complications after surgery.
To participate in this trial, patients must be at least 65 years old and scheduled for elective abdominal surgery that lasts more than two hours. They should also have been taking renin-angiotensin system inhibitors for over three months. If someone is interested in joining, they will need to provide informed consent, meaning they understand the study and agree to take part. The trial is currently recruiting participants and aims to find out if ciprofol can make a difference in how patients handle surgery safely.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing elective abdominal surgery under general anesthesia
- • 2. Duration of surgery exceeding 2 hours
- • 3. Patients receiving long-term renin-angiotensin system inhibitor therapy (\>3 months prior to surgery)
- • 4. Age ≥ 65 years
- • 5. ASA classification II-III
- • 6. Informed consent was obtained from patients or their guardians
- Exclusion Criteria:
- • 1. History of allergy to opioids, propofol, or ciprofol components.
- • 2. Anticipated difficult airway (limited mouth opening, restricted neck movement, or modified Mallampati grade III-IV) or difficult mask ventilation.
- • Body mass index ≤18 or ≥35 kg/m².
- • 3. Severe hepatic dysfunction (total bilirubin ≥3.0 mg/dL or AST/ALT ≥2 times the upper limit of normal).
- • 4. Severe renal impairment (creatinine clearance ≤30 mL/min).
- • 5. Cardiac diseases (AV block higher than first-degree, heart rate \<50 bpm, severe arrhythmias, severe valvular heart disease, heart failure, or unstable angina on the day of surgery).
- • 6. Preoperative cognitive impairment, cerebrovascular disease, or history of psychiatric illness.
- • 7. Abnormal thyroid-stimulating hormone levels or history of thyroid replacement therapy.
- • 8. Unstable asthma or history of asthma.
- • 9. Alcohol abuse, drug abuse, chronic opioid dependence, or analgesic use exceeding 3 months.
- • 10. Lactating or pregnant women.
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Min Yan
Study Director
Second Affiliated Hospital, School of Medicine, Zhejiang University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported